CDZ 173

Drug Profile

CDZ 173

Alternative Names: CDZ173

Latest Information Update: 26 May 2017

Price : $50

At a glance

  • Originator Novartis
  • Class Small molecules
  • Mechanism of Action Immunomodulators; Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Immunodeficiency disorders
  • Phase II Sjogren's syndrome

Most Recent Events

  • 26 May 2017 Novartis prematurely ends a phase II trial in Sjogren's syndrome in Poland (EudraCT2014-004616-12)
  • 08 Aug 2016 Novartis Pharmaceuticals plans a phase II/III extension trial for Immunodeficiency disorders (In adolescents, In adults) in USA, Netherlands, Czech Republic, United Kingdom, Ireland and Italy (PO) (NCT02859727)
  • 02 May 2016 Phase-II/III clinical trials in Immunodeficiency disorders in (In adolescents, In adults) in Netherlands (PO) (EudraCT2014-003876-22)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top